What we do

The first session of Catalonia.health’s new series brought a group of health-sector companies to Eurecat’s headquarters in Cerdanyola del Vallès, to get a close look at the technological infrastructure already within their reach.

The Parliament of Catalonia has approved, with no votes against, a motion urging the Government to allocate €7 million in 2027 to support Catalan industrial clusters. The clusters are asking for the funding to be made available during the first half of 2027, so that the resources can be deployed swiftly.

On 22 October, an institutional delegation from Gyeongsangbuk-do, one of the leading regions in biotechnology and biomedicine in South Korea, visited Catalonia.health to learn about the Catalan health ecosystem and explore avenues for collaboration in research and technological cooperation.

On 21 October, the Institute for Bioengineering of Catalonia (IBEC) celebrated its 20th anniversary with an institutional event at the Auditorium of the Fundació Joan Miró in Barcelona. The managing director of Catalonia.health, Laura Iglesias, attended the celebration.

On 21 October, Catalonia.health took part in the 5th session of the Community of R&D&I Knowledge Transfer Networks, an institutional event organised by the Department of Research and Universities of the Government of Catalonia. Our managing director, Laura Iglesias, and our project coordinator, Roser Alba, attended alongside the other clusters accredited by ACCIÓ and the R&D&I networks.

Maastricht / Heerlen, October 2026. A Catalonia.health delegation has taken part in the fourth study visit of the European project RISEMED4EU, held in Maastricht and Heerlen, in the Province of Limburg (Netherlands).

Sysmex Spain, a leading company specialising in healthcare technology and in vitro diagnostics, announces the move of its Spanish headquarters to a new space at SID Barcelona, the private science and innovation ecosystem in the city’s metropolitan area. SID Barcelona is a Catalonia.health member. Until now, Sysmex was based in the Barcelona-area town of Sant Just Desvern.

Catalonia.health took part on 2 October in the conference “European Health Data Space in Catalonia”, represented by Roser Alba, project coordinator, and Jordi Barretina, board member. The event presented the Health Data Access Body for Secondary Use (ODAS), which AQuAS will manage following its designation by the Government.

Bilbao hosted the 13th edition of BioSpain this week, Spain's leading biotech gathering and a key European reference in life sciences.

Barcelona has hosted this week the LSI Europe Summit 2026, one of the key international forums for medical technology and digital health companies seeking investment and global partnerships.

Peptomyc has announced the final closing of its equity financing round at €5.7 million, with a €0.7 million investment from the Institut Català de Finances (ICF). This is the first investment made through the Lidera Transferència en Salut fund, managed by the Government of Catalonia’s public development bank.

Partners from across Europe have officially launched IMPACT, a five-year Horizon Europe project developing new approaches to make personalised CAR Cell therapies faster and more reliable to manufacture, scalable and adaptable to individual patients.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, announced that the European Medicines Agency (EMA) has authorized its Clinical Trial Application (CTA) to initiate a Phase II study to evaluate vafidemstat for the treatment of Phelan-McDermid Syndrome (PMS).

BrainMapp Software Solutions has been set up as a spin-off of the Universitat Autònoma de Barcelona (UAB), a Catalonia.health member, and the Computer Vision Center (CVC), to bring to market a digital tool that helps neurosurgery teams identify the brain areas to preserve during tumour removal.

On 16 and 17 September, Barcelona brought together professionals from Europe and the United States for the first HYBRIDGE Annual Conference, a global community that connects science, business, regulation and innovation in the hybrid and 505(b)(2) ecosystem.

Both Catalonia.health member companies are joining forces to offer a comprehensive consultancy, digital transformation and regulatory compliance service to Life Sciences companies.

With this appointment, the organisation embarks on a new strategic phase focused on growing the association, strengthening connections between member companies and creating more value to its members.

CONNECTA Therapeutics has closed a €3.1 million round led by new investor Clave Capital, with support from existing backers Inveready, CDTI Innvierte, and Prous Institute for Biomedical Research. The funds will complete the ongoing Phase IIa trial of CTH120 in Fragile X syndrome, with preliminary results expected in mid-2027.

Minoryx Therapeutics, a member of Catalonia.health, and the Neuraxpharm Group have announced the completion of recruitment for the global Phase 3 CALYX clinical trial, which is evaluating leriglitazone (NEZGLYAL®) in adult male patients with cerebral adrenoleukodystrophy (cALD), a rare neurodegenerative disease with no approved pharmacological treatment options.

La firma de capital risc Asabys Partners, membre de Catalonia.health especialitzada en salut i ciències de la vida, participa com a co-líder en una ronda de finançament seed de 15 milions d'euros aixecada per iPremom, companyia de diagnòstic molecular dedicada a la predicció precoç de complicacions de l'embaràs.